Profile of disposition, tissue distribution and excretion of the novel anti-human immunodeficiency virus (HIV) agent W-1 in rats

다국어 초록 (Multilingual Abstract)

The purpose of this study was to characterize the disposition, distribution, excretion and plasma protein binding of 6-benzyl-1-benzyloxymethyl-5-iodouracil (W- 1) in rats. Concentrations of W-1 within biological samples were determined using a validated high performance liquid chromatography method. The plasma protein binding of W-1 was examined by equilibrium dialysis method. After oral administration of W-1 (50, 100 and 200 mg/kg, respectively) in self-microemulsifying drug delivery system formulation, the pharmacokinetic parameters of W-1 were as follows: the peak plasma concentrations (Cmax) were 0.42, 1.50 and 2.55 μg/mL, the area under the curve (AUC0-t) were 0.89, 2.27 and 3.96 lg/h mL and the plasma half-life (t1/2) were 5.15, 3.77 and 3.77 h, respectively.
Moreover, the prototype of W-1 was rapidly and extensively distributed into fifteen tissues, especially higher concentrations were detected in intestine, stomach and liver, respectively. The plasma protein binding of W-1 in rat, beagle dog and human were in the range of 97.96–99.13 %. This study suggested that W-1 has an appropriate pharmacokinetics in rats, such as rapid absorption, moderate clearance, and rapid distribution to multiple tissues. Those properties provide important information for further development W-1 as an anti-HIV-1 drug candidate.

참고문헌 (Reference)

1 Dueweke TJ, "U-90152, a potent inhibitor of human immunodeficiency virus type 1 replication" 37 : 1127-1131, 1993

2 Wright DW, "Thumbs down for HIV: domain level rearrangements do occur in the NNRTI-bound HIV-1 reverse transcriptase" 134 : 12885-12888, 2012

3 Snedecor SJ, "The prevalence of transmitted resistance to first-generation non-nucleoside reverse transcriptase inhibitors and its potential economic impact in HIV-infected patients" 8 : e72784-, 2013

4 Sluis-Cremer N, "The emerging profile of cross-resistance among the nonnucleoside HIV-1 reverse transcriptase inhibitors" 6 : 2960-2973, 2014

5 Lu X, "The design and synthesis of N-1-alkylated-5-aminoarylalkylsubstituted- 6-methyluracils as potential non-nucleoside HIV-1 RT inhibitors" 15 : 7399-7407, 2007

6 Jonckheere H, "The HIV-1 reverse transcription (RT) process as target for RT inhibitors" 20 : 129-154, 2000

7 Andries K, "TMC125, a novel next-generation nonnucleoside reverse transcriptase inhibitor active against nonnucleoside reverse transcriptase inhibitor-resistant human immunodeficiency virus type 1" 48 : 4680-4686, 2004

8 Qin H, "Synthesis and biological evaluation of novel C5 halogen-functionalized S-DABO as potent HIV-1 nonnucleoside reverse transcriptase inhibitors" 18 : 3231-3237, 2010

9 Ren J, "Structural basis for drug resistance mechanisms for non-nucleoside inhibitors of HIV reverse transcriptase" 134 : 157-170, 2008

10 Singh K, "Structural aspects of drug resistance and inhibition of HIV-1 reverse transcriptase" 2 : 606-638, 2010

11 Lamson MJ, "Single dose pharmacokinetics and bioavailability of nevirapine in healthy volunteers" 20 : 285-291, 1999

12 Babkov DA, "Scaffold hopping: exploration of acetanilide- containing uracil analogues as potential NNRTIs" 23 : 1069-1081, 2015

13 Garvey L, "Rilpivirine: a novel non-nucleoside reverse transcriptase inhibitor" 18 : 1035-1041, 2009

14 Li N, "Recent developments in sample preparation and data pre-treatment in metabonomics research" 589 : 4-9, 2016

15 Davies B, "Physiological parameters in laboratory animals and humans" 10 : 1093-1095, 1993

16 Lihua Chen, "Pharmacokinetics, tissue distribution and excretion of peimisine in rats assessed by liquid chromatography-tandem mass spectrometry" 대한약학회 38 (38): 1138-1146, 2015

17 Minematsu T, "Pharmacokinetics, distribution and excretion of YM155 monobromide, a novel small-molecule survivin suppressant, in male and pregnant or lactating female rats" 33 : 160-169, 2012

18 Mekjaruskul C, "Pharmacokinetics, bioavailability, tissue distribution, excretion, and metabolite identification of methoxyflavones in Kaempferia parviflora extract in rats" 40 : 2342-2353, 2012

19 Liang Feng, "Pharmacokinetics, Tissue Distribution, Metabolism, and Excretion of Ginsenoside Rg1 in Rats" 대한약학회 33 (33): 1975-1984, 2010

20 김학재, "Pharmacokinetics and Tissue Distribution of Psammaplin A, a Novel Anticancer Agent, in Mice" 대한약학회 35 (35): 1849-1854, 2012

21 Li A, "Novel pyridinone derivatives as non-nucleoside reverse transcriptase inhibitors (NNRTIs) with high potency against NNRTI-resistant HIV-1 strains" 56 : 3593-3608, 2013

22 Tronchet JM, "Nonnucleoside inhibitors of HIV-1 reverse transcriptase: from the biology of reverse transcription to molecular design" 3 : 1496-1511, 2003

23 Melikian GL, "Non-nucleoside reverse transcriptase inhibitor (NNRTI) crossresistance: implications for preclinical evaluation of novel NNRTIs and clinical genotypic resistance testing" 69 : 12-20, 2014

24 Moore JP, "New targets for inhibitors of HIV-1 replication" 1 : 40-49, 2000

25 Kim TH, "In vivo absorption and disposition of a-cedrene, a sesquiterpene constituent of cedarwood oil, in female and male rats" 30 : 168-173, 2015

26 Tang H, "Important roles of the hyphenated HPLC-DAD-MS-SPE-NMR technique in metabonomics" 47 (47): S157-S162, 2009

27 Powles T, "Highly active antiretroviral therapy and the incidence of non-AIDS-defining cancers in people with HIV infection" 27 : 884-890, 2009

28 Agneskog E, "Evaluation of etravirine resistance in clinical samples by a simple phenotypic test" 85 : 703-708, 2013

29 Cohen CJ, "Efficacy and safety of rilpivirine (TMC278) versus efavirenz at 48 weeks in treatment-naive HIV-1-infected patients: pooled results from the phase 3 double-blind randomized ECHO and THRIVE Trials" 60 : 33-42, 2012

30 Marzolini C, "Efavirenz plasma levels can predict treatment failure and central nervous system side effects in HIV-1-infected patients" 15 : 71-75, 2001

31 Rakhmanina NY, "Efavirenz in the therapy of HIV infection" 6 : 95-103, 2010

32 Lu YY, "Development and validation of a high performance liquid chromatography method for determination of 6-benzyl-1-benzyloxymethyl-5-iodouracil (W-1), a novel nonnucleoside reverse transcriptase inhibitor and its application to a pharmacokinetic study in rats" 29 : 1548-1552, 2015

33 Wang X, "Design, synthesis, and biological evaluation of 1-[(2-benzyloxyl/alkoxyl)methyl]-5-halo-6-aryluracils as potent HIV-1 non-nucleoside reverse transcriptase inhibitors with an improved drug resistance profile" 55 : 2242-2250, 2012

34 Gallien S, "Archived HIV-1 DNA resistance mutations to rilpivirine and etravirine in successfully treated HIV-1-infected individuals pre-exposed to efavirenz or nevirapine" 70 : 562-565, 2015

35 Asahchop EL, "Antiviral drug resistance and the need for development of new HIV-1 reverse transcriptase inhibitors" 56 : 5000-5008, 2012

36 De Clercq E, "Antiretroviral drugs" 10 : 507-515, 2010

37 Kim Y, "Absorption, distribution, metabolism and excretion of gemigliptin, a novel dipeptidyl peptidase IV inhibitor, in rats" 44 : 627-634, 2014

38 Zhang XM, "A novel mutation, D404 N, in the connection subdomain of reverse transcriptase of HIV-1 CRF08_BC subtype confers cross-resistance to NNRTIs" 70 : 1381-1390, 2015